Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy

British Journal of Cancer

Volumn 85, Issue 8, 2001, Pages 1099-1101

  De Wit, R ^a   De Boer, A C ^a   Vd Linden, G H M ^a   Stoter, G ^a   Sparreboom, A ^a   Verweij, J ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GRANISETRON; ONDANSETRON; SEROTONIN 3 ANTAGONIST;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS RESISTANCE; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG STRUCTURE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STRUCTURE ANALYSIS; TREATMENT FAILURE; TREATMENT PLANNING; VOMITING;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CROSS-OVER STUDIES; DEXAMETHASONE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GRANISETRON; HUMANS; MALE; MIDDLE AGED; ONDANSETRON; VOMITING;

EID: 0035914250     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2001.2045     Document Type: Article

References (15)

1. 3 antagonists; a pilot study
2. Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administration
3. Antiemetic therapy
4. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis
5. Intravenous granisetron establishing the optimal dose
6. Comparative crossover trial of two intravenous doses of granisetron (1 mg vs 3 mg) + dexamethasone in the prevention of acute cisplatinum-induced emesis
7. Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), Granisetron (Kytril), and Tropisetron (Navoban)
8. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatininduced emesis
9. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin
10. Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis
11. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: A multicenter, double-blind, randomized parallel study
12. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy
13. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: A multicentre double-blind, randomized parallel-group study
14. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: A multicentre, double-blind, dboule-dummy, randomized, parallel-group study
15. Optimal control of acute cisplatin-induced emesis